The Chinese-German Journal of Clinical Oncology

, Volume 1, Issue 3, pp 141–144 | Cite as

Therapy of multiple myeloma

  • H. Goldschmidt 
  • F. W. Cremer 
  • Th. Möhler 
  • A. Krämer 
  • M. Görner 
  • G. Egerer 
  • A. D. Ho 
Original Articles
  • 15 Downloads

Summary

Multiple Myeloma (MM) is characterised by the accumulation of malignant plasma cells in the bone marrow producing a monoclonal immunoglobulin. The standard conventional therapy is the combination of melphalan and prednisone resulting in a response rate of 40%–60% and in a median survival time of approximately 3 years. In order to improve the therapeutic efficacy various combination regimens have been tested. Most randomized trials have frailed to show a significant improvement in survival time when combination chemotherapy is used instead of melphalan with or without prednisone. The benefit of maintenance therapy with interferon-alpha has been demonstrated. The toxicity of interferon-alpha, which may reduce the quality of life, should be considered. Recently, myeloma-treatment has been modified. High-dose chemotherapy accompanied by hematopoietic stem-cell support via autologous transplant is recommended up to the age of 65–70 years. First results from a French study comparing single versus double autologous transplantation have shown a benefit in terms of event-free survival for the sequential approach. Vaccinations as an adoptive immuntherapy to treat minimal residual disease are under way. The mortality rate of allogeneic transplantation of hematopoietic stem cells has been reduced in the last 5 years. The use of reduced conditioning regimens or the partial depletion of T cells in peripheral blood stem cell transplants in an effort to decrease transplant related mortality are promising approaches. Thalidomide and its derivates are a new class of agents with independent anti-tumour activity in MM. Encouraging results with this antiangiogenic therapy in phase II trials have been reported. Supportive therapies, such as the treatment of anaemia with erythropoietin, the management of renal failure and the use of bisphosphonates, improve the life quality of MM patients.

Key words

multiple myeloma treatment transplantation angiogenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexanian R, Dreicer R. Chemotherapy for multiple myeloma. Cancer, 1984, 53: 583–588.CrossRefPubMedGoogle Scholar
  2. 2.
    Samson D. Principles of chemotherapy and radiotherapy. In: Multiple Myeloma, eds. Gahrton G, Durie GM. Arnold, London, Sydney, Auckland, 1996. 108–129.Google Scholar
  3. 3.
    Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: An overview of published trials. J Clin Oncol, 1992, 10: 334–342.PubMedGoogle Scholar
  4. 4.
    Wheatley K. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6 633 patients from 27 randomised trials. J Clin Oncol, 1998, 16: 3832–3842.Google Scholar
  5. 5.
    Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma resistant to alkylating agents. New Engl J Med, 1984, 310: 1353–1356.CrossRefPubMedGoogle Scholar
  6. 6.
    Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol, 2000, 11: 615.CrossRefGoogle Scholar
  7. 7.
    Ludwig H, Fritz E, Neuda J, et al. Patients preferences for interferon alpha in multiple myeloma. J Clin Oncol, 1997, 15: 1672–1679.PubMedGoogle Scholar
  8. 8.
    Attal M, Harousseau JL, Stoppa AM, et al. A Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 1999, 335: 91–97.CrossRefGoogle Scholar
  9. 9.
    Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood, 1999, 93: 55–65.PubMedGoogle Scholar
  10. 10.
    Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood, 2000, 95: 6–11.Google Scholar
  11. 11.
    Siegel DS, Desikan KR, Mehta J, et al. Age is not a prognostic factor variable with autotransplants for multiple myeloma. Blood, 1999, 93: 51–54.PubMedGoogle Scholar
  12. 12.
    Moreau P, Facon T, Attal M, et al. Comparison of 200mg/m2 melphalan and 8 Gy total body irradiation plus 140mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood, 2002, 99: 731–735.CrossRefPubMedGoogle Scholar
  13. 13.
    Attal M, Harousseau JL. Autograft and multipe myeloma: experience of the IMF. Bull Cancer, 2001, 88: 888–892.PubMedGoogle Scholar
  14. 14.
    Goldschmidt H, Bouko Y, Bourhis JH, et al. CD34+ selected PBPCT results in an increased infective risk without prolongation of event free survival in newly diagnosed myeloma: a randomised study from the EBMT. Blood, 2000, 96: 558a (abstract).Google Scholar
  15. 15.
    Attal M, Harousseau JL, Facon T. Single versus double transplant in myeloma: a randomized trial of the IFM. Proceed VIII th International Myeloma Workshop. 2001, S15: 28 (abstract).Google Scholar
  16. 16.
    Kyle RA. Current therapy of multiple myeloma. Intern Med, 2002, 41: 175–180.CrossRefPubMedGoogle Scholar
  17. 17.
    Pfeiffer S, Gooding R, Apperley J, et al. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol, 1997, 98: 973–982.CrossRefPubMedGoogle Scholar
  18. 18.
    Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: A comparision between transplants performed 1983–1993 and 1994–1998 at Europe Group for Blood and Bone Marrow Transplantation centers. Brit J Haematol, 2002. 209–216.Google Scholar
  19. 19.
    Lalancette MRK, Sydlo R, Mackinnon S, et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: the European Group for Blood and Marrow Transplantation (EBMT) experience. In: American Society of Hematology (ASH); 2000: Blood; 2000, abstract.Google Scholar
  20. 20.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 1997, 90: 4206–4211.PubMedGoogle Scholar
  21. 21.
    Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, 99: 75–82.CrossRefPubMedGoogle Scholar
  22. 22.
    Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med, 1999, 341: 1656–1671.CrossRefGoogle Scholar
  23. 23.
    Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clincial Cancer Research (in press).Google Scholar
  24. 24.
    Moehler TM, Neben K, Benner A, et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood, 2001, 15: 3846–3848.CrossRefGoogle Scholar
  25. 25.
    Garton JP, Gertz MA, Witzig TE, et al. Epoetin alfa for the treatment of anemia of multiple myeloma. Achr Intern Med, 1995, 155: 2069–2074.CrossRefGoogle Scholar
  26. 26.
    Oken MM, Pomeroy C, Weisdorf D, et al. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med, 1996, 100: 624–628.CrossRefPubMedGoogle Scholar
  27. 27.
    Djulbegovic B, Wheatley K, Ross J, et al. Bisphosphonates ion multiple myeloma. Chochr. Database Syst Rev, 2001, 9: CD003188.Google Scholar

Copyright information

© Editorial Office of The Chinese-German Journal of Clinical Oncology 2002

Authors and Affiliations

  • H. Goldschmidt 
    • 1
  • F. W. Cremer 
    • 1
  • Th. Möhler 
    • 1
  • A. Krämer 
    • 1
  • M. Görner 
    • 1
  • G. Egerer 
    • 1
  • A. D. Ho 
    • 1
  1. 1.Department of Internal Medicine VUniversity of HeidelbergHeidelbergGermany

Personalised recommendations